sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
Published 4 years ago • 56 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
2:18
the combination of ibrutinib and obinutuzumab in cll
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
1:37
causes & management of ibrutinib discontinuation in cll
-
10:20
eha22: time-limited venetoclax-obinutuzumab /- ibrutinib is superior to chemoimmunotherapy in ...
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
25:45
haemato-oncology applications of bcr immune repertoire sequencing
-
4:43
phase ib trial of ianalumab plus ibrutinib for cll
-
0:49
overview of the cll2-big trial of ibrutinib and obinutuzumab
-
4:13
benefit trial: isatuximab, lenalidomide, and dexamethasone /- bortezomib in newly diagnosed myeloma
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
2:15
cd8 t cell expansion in cll patients treated with ibrutinib
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:05
alnuctamab: improved route of administration and optimized dose level & dosing schedule
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data